Den Europæiske Union - dansk - EMA (European Medicines Agency)

n.v. organon - colecalciferol, alendronic acid (as sodium trihydrate) - osteoporose, postmenopausale - narkotika til behandling af knoglesygdomme - behandling af postmenopausal osteoporose hos patienter med risiko for vitamin d-insufficiens. adrovance reducerer risikoen for vertebrale og hoftebrud.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

n.v. organon - alendronsyre, colecalciferol - osteoporose, postmenopausale - narkotika til behandling af knoglesygdomme - behandling af postmenopausal osteoporose hos patienter med risiko for vitamin d-insufficiens. fosavance reducerer risikoen for vertebrale og hoftebrud.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

n.v. organon - alendronsyre, colecalciferol - osteoporose, postmenopausale - narkotika til behandling af knoglesygdomme - behandling af postmenopausal osteoporose hos patienter med risiko for vitamin d-insufficiens. vantavo reducerer risikoen for vertebrale og hoftebrud. behandling af postmenopausal osteoporose hos patienter, der ikke får d-vitamin d-tilskud, og er i risiko for d-vitamin d-insufficiens. vantavo reducerer risikoen for vertebrale og hoftebrud.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - alfa-tocopherol, all-rac-, ascorbinsyre, biotin, cholecalciferol, cyanocobalamin, dexpanthenol, folsyre, nicotinamid, phytomenadion, pyridoxinhydrochlorid, retinolpalmitat, riboflavinnatriumphosphathydrat, thiaminhydrochlorid - pulver til infusionsvæske, opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

boehringer ingelheim animal - alfa-tocopherylacetat, racemisk, cholecalciferoldiluendum, vitamin a diluendum - injektionsvæske, opløsning

Den Europæiske Union - dansk - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkotika til behandling af knoglesygdomme - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

bela-pharm gmbh & co. kg - borsyre, calciumgluconat (monohydrat), magnesiumchloridhexahydrat - infusionsvæske, opløsning - 380+60+50 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

vifor fresenius medical care renal pharma france - calcifediol - depotkapsler, bløde - 30 mikrogram

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

europharma.dk aps - carbamazepin - depottabletter - 400 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

baxter a/s - alanin, arginin, calciumchloriddihydrat, fiskeolie, glucosemonohydrat, glycin, histidin, isoleucin, kaliumchlorid, leucin, lysinhydrochlorid, magnesiumsulfatheptahydrat, methionin, natriumacetattrihydrat, natriumglycerophosphat, hydreret, olivenolie, renset, phenylalanin, prolin, serin, soyaolie, threonin, triglycerider, middelkædelængde, tryptophan, tyrosin, valin, zinksulfat heptahydrat - infusionsvæske, emulsion